RecruitingNot ApplicableNCT05061680

Quick Large Balloon Dilatation for Removal of Large Bile Duct Stones (SHODBADI)

Endoscopic Papillary Short Duration Large Balloon Dilatation for Removal of Large Bile Duct Stones: a Prospective Multicenter Study of Short and Long-term Adverse Events


Sponsor

Helsinki University Central Hospital

Enrollment

600 participants

Start Date

Apr 5, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

ESGE guidelines suggests 30-60 seconds endoscopic large balloon papillary dilation from the disappearance of the waist of the papilla. The investigators have good results in stone removal with much quicker dilatations when the cholangiogram is followed and the dilation is finished as soon as the disappearance of the waist of the papilla is seen. This Scandinavian multicenter prospective study is especially interested in stone clearance rate and short and long-term adverse events such as pancreatitis, cholangitis, bleeding, perforations, residual biliary stones, and newly developing biliary stones.


Eligibility

Min Age: 18 YearsMax Age: 95 Years

Inclusion Criteria2

  • Age \>18 years
  • Common bile duct stone \>10mm diameter

Exclusion Criteria8

  • Altered anatomy after surgery (B II, Roux-en-Y reconstruction)
  • Common bile duct cysts
  • Acute pancreatitis
  • Distal common bile duct stricture or tumor
  • Coagulation disorders
  • Ongoing coagulation medication
  • Pregnancy
  • Inability to give an informed consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEendoscopic short duration papillary large balloon dilation

During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.


Locations(2)

Helsinki University Hospital

Helsinki, Finland

Turku University Hospital

Turku, Finland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05061680


Related Trials